13 March 2024 : Review article
A Review of the Resurgence of Measles, a Vaccine-Preventable Disease, as Current Concerns Contrast with Past Hopes for Measles Elimination
Dinah V. Parums1BCDEFDOI: 10.12659/MSM.944436
Med Sci Monit 2024; 30:e944436
Table 2 US Recommendations: Measles, mumps, and rubella (MMR) vaccination [23].
| Population groups | Vaccination recommendations |
|---|---|
| Children between 12 to 15 months of age | First dose of the MMR vaccine |
| Children between 4 to 6 years of age | Second dose of the MMR vaccine (the second dose can be given earlier if given after at least 28 days after the first dose) |
| Children between 12 months and 6 years of age | The measles, mumps, rubella, and varicella (chickenpox) (MMRV) vaccine as a single dose |
| Students in higher educational institutions without presumptive evidence of measles virus immunity | Two doses of MMR vaccine, separated by at least 28 days |
| Adults without presumptive evidence of measles virus immunity | A single dose of MMR vaccine |
| Adults without presumptive evidence of measles virus immunity who are at increased risk of infection: students at higher education institutions; healthcare personnel; international travelers | Two doses of MMR vaccine, separated by at least 28 days |
| Non-pregnant women of childbearing age who do not have presumptive evidence of immunity | At least a single dose of MMR vaccine |
| Women who are breastfeeding and do not have presumptive evidence of immunity | At least a single dose of MMR vaccine while breastfeeding, as the vaccine is not passed to the baby in breast milk |
| Modified from: Centers for Disease Control and Prevention (CDC), 26 January 2021 []. | |






